ArticleClinical ophthalmology (Auckland, N.Z.)2022

Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions.

James E Deom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.